Last reviewed · How we verify
Epoetin alfa vials
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients undergoing elective surgery.
At a glance
| Generic name | Epoetin alfa vials |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This leads to increased reticulocyte production and elevation of hemoglobin and hematocrit levels. It is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in cancer patients receiving chemotherapy
- Anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Thrombotic events (deep vein thrombosis, pulmonary embolism)
- Headache
- Injection site reactions
- Fever
- Pure red cell aplasia (rare)
Key clinical trials
- Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (PHASE2)
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes (PHASE3)
- Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe) (PHASE2)
- Traumatic Optic Neuropathy Treatment Trial 2 (PHASE3)
- High-dose Erythropoietin for Asphyxia and Encephalopathy (PHASE3)
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) (PHASE3)
- Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia (PHASE2)
- A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin alfa vials CI brief — competitive landscape report
- Epoetin alfa vials updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI